Discovery and optimization of isoliquiritigenin as a death-associated protein kinase 1 inhibitor.

Death-associated protein kinase 1 Inhibitor Protein crystallography isoliquiritigenin

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
04 Sep 2024
Historique:
received: 07 08 2024
revised: 01 09 2024
accepted: 02 09 2024
medline: 8 9 2024
pubmed: 8 9 2024
entrez: 7 9 2024
Statut: aheadofprint

Résumé

Death-associated protein kinase 1 (DAPK1) is a phosphotransferase in the serine/threonine kinase family. Inhibiting DAPK1 is expected to be beneficial in treating Alzheimer's disease and protecting neuronal cells during cerebral ischemia. In this study, we demonstrated that the natural chalcone isoliquiritigenin inhibits DAPK1 in an ATP-competitive manner, and we synthesized halogen derivatives to amplify the inhibitory effect. Among the compounds tested, the chlorine, bromine, and iodine derivatives exhibited high DAPK1 inhibitory activity and binding affinity. Crystal structure analysis revealed that this improvement is attributable to the halogen atoms fitting well into the hydrophobic pocket formed by I77, L93, and I160. In particular, the chlorine derivative showed a significant enthalpic contribution to the interaction with DAPK1, suggesting its potential as a primary compound for new DAPK1 inhibitors.

Identifiants

pubmed: 39243455
pii: S0223-5234(24)00717-7
doi: 10.1016/j.ejmech.2024.116836
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116836

Informations de copyright

Copyright © 2024 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Takeshi Yokoyama (T)

Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0914, Japan. Electronic address: tyokoya3@pha.u-toyama.ac.jp.

Kotono Hisatomi (K)

Graduate School of Pharma-Medical Sciences, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.

Saki Oshima (S)

Graduate School of Pharma-Medical Sciences, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.

Ichiro Tanaka (I)

Graduate School of Science and Engineering, Ibaraki University, Nakanarusawa 4-12-1, Hitachi, Ibaraki, 316-8511, Japan.

Takuya Okada (T)

Graduate School of Pharma-Medical Sciences, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.

Naoki Toyooka (N)

Graduate School of Pharma-Medical Sciences, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.

Classifications MeSH